
Novo Nordisk Raises 2026 Outlook as Wegovy Pill Drives Stronger Q3 Earnings
Novo Nordisk raised its 2026 outlook on 4 November after reporting better-than-expected third-quarter adjusted profit. The company reported adjusted operating profit of DKK 31.72 billion and adjusted quarterly sales of approximately DKK 79.20 billion. Its Wegovy pill generated DKK 5.39 billion in quarterly revenue. Novo now expects full-year adjusted sales and adjusted operating profit growth at constant exchange rates to range from a decline of 2% to growth of 2%, versus a previously weaker outlook. The company also reported impairment charges that weighed on reported operating profit, so adjusted and reported earnings should not be conflated. Reuters reported that shares initially rose after the announcement.





























